CD276 and neuroblastoma: To date, eight clinical trials are currently treating NB patients with antibodies against IC molecules: three of them are using Nivolumab, Dostarlimab or Pembrolizumab (anti-PD-1 antibodies), four of them are based on the administration of Ipilimumab (anti-CTLA-4 antibody), and the last one is employing Enoblituzumab (anti-B7-H3 antibody) (www.clinicaltrials.gov accessed on 30 January 2022).